Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115338 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yingying Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Complement C5a, Antibodies, Monoclonal. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The complement-activated product (C5a) is a key mediator in the pathogenesis of acute respiratory distress syndrome (ARDS). While blocking C5a represents a promising therapeutic strategy, novel anti-C5a therapies require further development. PURPOSE: This study aimed to develop a novel, human anti-C5a monoclonal antibody (STSA-1002) and evaluate its efficacy in treating ARDS through in vitro and vivo studies. RESULTS: In vitro, STSA-1002 exhibited high binding affinity to human and rhesus monkey C5a (EC50: 29.41 ± 10.74 ng/mL and 32.29 ± 10.96 ng/mL, respectively) and effectively inhibited C5a-induced neutrophil degranulation, chemotaxis, and CD11b expression. In vivo, single intravenous administration of STSA-1002 (1, 3 and 10 mg/kg) significantly reduced the levels of interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1 (MCP-1) and mortality in a COVID-19-related LPS-induced ARDS mouse model (Model 1). In a second LPS-induced ARDS model (Model 2), STSA-1002 (1, 5 and 25 mg/kg) significantly reduced IL-6, TNF-α concentrations and leukocyte counts in serum and diminished IL-6 in bronchoalveolar lavage fluid (BALF), alongside improvements in lung weight index. In addition, pharmacokinetic (PK) studies in rhesus monkeys demonstrated linear exposure (5-50 mg/kg) and a favorable safety profile in a 4-week repeat-dose toxicity study. CONCLUSION: These results furnish comprehensive preclinical evidence for STSA-1002 as an innovative anti-C5a therapeutic agent and provide a preliminary rationale for developing immunomodulatory therapy in ARDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
- Staidson Biopharmaceuticals (Beijing) Co., Ltd, Beijing 100176, China.
- Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China. Electronic address: wangxh@bjsjth.cn.
Zitieren
APA
Fang, Y., Wang, X., Xu, C., Zhu, Q., Zang, X., Liu, J., Zhang, J., & Wang, X. (2025). Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115338
Vancouver
Fang Y, Wang X, Xu C, Zhu Q, Zang X, Liu J, et al. Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115338
BibTeX
@article{Fang2025,
author = {Fang, Yingying and Wang, Xiaoqian and Xu, Chang and Zhu, Qing and Zang, Xin and Liu, Ju and Zhang, Jingyi and Wang, Xinghe},
title = {Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115338}
}
EUVIMED